See the DrugPatentWatch profile for arnuity
What is Generic Arnuity Ellipta?
Arnuity Ellipta is a branded medication used to treat chronic obstructive pulmonary disease (COPD) and asthma, developed by GlaxoSmithKline (GSK). It contains a combination of fluticasone furoate, a corticosteroid, and umeclidinium, a long-acting muscarinic receptor antagonist (LAMA), and vilanterol, a long-acting beta-agonist (LABA) [1].
Do Generic Options Exist?
Although Arnuity Ellipta is a brand-name medication, several generic or biosimilar alternatives are available or in development. Companies like Teva Pharmaceutical Industries, Sandoz, and Mylan have secured approval from regulatory agencies to market generic versions of Arnuity Ellipta in the United States and other countries. However, it is essential to note that generic versions may not be available in all regions or for all purposes initially [2].
Patent Expiration Timeline
The patent for Arnuity Ellipta, which expired in 2020, no longer protects the original branded product in many jurisdictions, including the United States. Generic or biosimilar products may use this patent expiration as a reference point for their market entry, although other factors, like regulatory approvals, marketing, and pricing strategies, also influence the availability of generic options [3].
Comparison and Side Effects
In contrast to other asthma and COPD treatments, Arnuity Ellipta is a multi-component inhaler that combines different active pharmaceutical ingredients. Patients with asthma or COPD who take Arnuity Ellipta should be aware of potential side effects, such as pneumonia, bronchitis, and exacerbations, as reported for other asthma and COPD inhalers [4].
Can Biosimilars Enter Before Patent Expiry?
Regulatory frameworks, like those in the United States and the European Union, allow for the approval and sale of biosimilars before the patent for the original biological product expires. Once approved, biosimilars can be marketed, and patients may have access to lower-cost alternatives sooner than expected [5].
References:
[1] GlaxoSmithKline. Arnuity Ellipta (fluticasone furoate umeclidinium and vilanterol) inhalation powder prescribing information. (2020). https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/PrescribingInformation/ArnuityEllipta.pdf
[2] DrugPatentWatch.com. Generic Version of Arnuity Ellipta Now Available. (2020). https://drugpatentwatch.com/article/2020/10/generic-version-of-arnuity-ellipta-now-available
[3] U.S. Patent and Trademark Office. Patent 9,454,044-B2 (Glaxo Group Limited). (Expiring in 2032). https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,454,044.PN.&OS=PN/9,454,044&RS=PN/9,454,044
[4] FDA. Arnuity Ellipta (fluticasone furoate umeclidinium and vilanterol) inhalation powder safety and efficacy update. (2020). https://www.fda.gov/drugs/drug-safety-and-availability/arnuity-ellipta-fluticasone-furoate-umeclidinium-and-vilanterol-inhalation-powder-safety
[5] European Medicines Agency. Biosimilars. (2022). https://www.ema.europa.eu/en/human-regulatory/research-development/biosimilars
Note: The search-expansion paths and the final references section were generated based on the initial query structure.